{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-26-004488","form_type":"8-K","ticker":"EBRCZ","cik":"0001347123","company_name":"EBR Systems, Inc.","filed_at":"2026-04-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.179432+00:00","generated_at":"2026-05-15T06:46:27.274628+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"EBR Systems Q1 preliminary revenue $2.25-$2.36M; commercial cases double QoQ","bullets":["Preliminary unaudited Q1 2026 revenue $2.25M-$2.36M; financial close not yet complete.","41 WiSE implants in Q1 2026, more than double Q4 2025; cumulative 71 commercial implants.","Added 16 purchase agreements (total 37) and 22 trained physicians (total 55) in Q1.","1-for-10 reverse stock split effective April 1; CDI conversion ratio changed to 10:1.","Management cites strong commercial momentum, expanding site readiness and physician training."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-26-004488","json":"https://secwatch.observer/filing/0001214659-26-004488.json","markdown":"https://secwatch.observer/filing/0001214659-26-004488.md","text":"https://secwatch.observer/filing/0001214659-26-004488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347123/000121465926004488/0001214659-26-004488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347123/000121465926004488/z482608k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:46:27.274628+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3c33441370173d602c526af7f97d86e6d8f2ce3","claim":"EBR Systems, Inc. reported the first quarter ended March 31, 2026 results: revenue US$2.25M to US$2.36M.","evidence_excerpt":"in 41 commercial patients during the quarter, bringing total implants across the pilot phase and Limited Market Release to 71 · EBR expects to report revenue in the range of US$2.25M to US$2.36M for Q1 2026, based on preliminary unaudited quarter-end results and subject to quarter-end closing adjustments · The Limited Market Release continued to advance in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1347123/000121465926004488/0001214659-26-004488-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"US$2.25M to US$2.36M"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}